Treatment of Patients with Refractory Functional Dyspepsia Using *Nardostachys jatamansi* (D.Don) DC.
Hydroalcoholic Extract: A Case Series

Mohaddese Mirzapour¹, Morteza Mojahedi¹,2,3, Javad Shokri⁴, Soraya Khafri⁵, Zahra Memariani¹,2,*

¹Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran
²Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
³Department of History of Medical Sciences, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran
⁴Research Center for Infectious Diseases and Tropical Medicine, Health Research Center, Babol, University of Medical Sciences, Babol, Iran
⁵Department of Statistic and Epidemiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran

Received: 10 Jul 2017  Revised: 12 Aug 2017  Accepted: 19 Aug 2017

Abstract

Functional dyspepsia (FD) is a highly prevalent condition with high impact on healthcare costs. Considering the complimentary therapies options like phytotherapy, this study aimed to investigate the efficacy and safety of *Nardostachys jatamansi* (D.Don) DC. extract in sixteen FD patients. The subjects received capsules of 500 mg *N. Jatamansi*, 3 times daily before meals for 30 days. The severity of early satiation and postprandial fullness were assessed by self-report of improvement at least 50% of symptoms and other FD symptoms assessed by Gastrointestinal Symptom Rating Scale (GSRS) before intervention and at end of treatment. The mean GSRS score level decreased significantly after intervention among study population. Five patients had chief complaint of early satiety and post prandial fullness who all of them reported 50% improvement. According to the results *N. jatamansi* seems to be effective in patients with refractory FD. Randomized clinical studies seem to be required.

Keywords: Dyspepsia; Herbal medicine; *N. jatamansi*; Traditional medicine


*Corresponding Author: Zahra Memariani
Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran
Tel: +981132194728
Fax: +981132194728
E-mail: memarianiz@gmail.com, z.memariani@mubabol.ac.ir
**Introduction**

Functional dyspepsia (FD) is a highly prevalent condition with high impact on socio-economic and healthcare costs. Its diagnosis is generally based on four symptoms including epigastric pain and burning, early satiety, postprandial fullness, for three months with symptom onset more than six months, without evidence of other organic, systemic, metabolic or structural disease [1-3].

The reported prevalence of dyspepsia varies depending on geographical definition and location and it is represented in a systematic review in the range of 10-40% [4,5]. Dyspepsia is estimated to affect up to 29.9% of the Iranian population [6]. According to the Rome III criteria, FD patients were divided into two groups, including subjects with “epigastric pain syndrome (EPS)” and those with “postprandial distress syndrome (PDS)”[7]. The overlap of PDS and EPS is considered as a new variant in Rome IV criteria [8]. The underlying pathophysiology of these two categories might be heterogeneous so it is required to have different approaches in treatments [9]. Delayed gastric emptying of solids is reported in a large proportion (up to 40%) of patients with functional dyspepsia and mainly treated with prokinetic drugs [10,11]. However, the results of prokinetic medications efficacy in the treatment of FD patients are unclear [12]. Generally, several complimentary therapies options like phytotherapy are available for managing patients with functional dyspepsia [13].

Some natural products have been traditionally used in Persian Medicine (PM) with a long history of use in the treatment of gastrointestinal diseases. They have also gained patients’ better acceptance than conventional therapeutic agents [14-17]. Today, there are some clinical studies based on PM in treatment of FD [18-21]. *N. jatamansi* has long been used as a remedy in treatment of some diseases like central nervous system (CNS) disorders [22]. The medicinal properties of its rhizome are well-documented in traditional medicinal systems including Ayurveda, Persian and Chinese medicine for the treatment of digestive and neuro-psychiatric disorders [23,24]. Along with many studies representing its efficacy in CNS diseases [25], there are only some animal studies that indicate its effect in gastrointestinal filed [23,26].

Therefore, this pilot study aimed to investigate the therapeutic efficacy and safety of *N. jatamansi* hydroalcoholic extract in patients with functional dyspepsia.

**Methods**

**Study design and subjects**

This pilot clinical trial study was conducted on sixteen FD patients, in Persian medicine clinic, Babol, Iran. FD was diagnosed clinically by a gastroenterologist, according to Rome IV criteria. Endoscopy was performed for patients over the age of 55 years and patients with symptoms including unexplained weight loss, odynophagia, dysphagia, family history of gastrointestinal cancer. These patients had symptoms of FD in the last six months before this study, and some of them were taken the routine treatments like antacid drugs or prokinetic agent, etc., without satisfactory effect. Individuals taking routine medication were included in this study and patients with problems such as drug resistance, under the supervision of a gastroenterologist, their routine medication was discontinued. All patient’s voluntary entered the study after the complete explanation of the drug safety profile. Written informed consent was obtained from all of them. We reassured all patients that they will access trained traditional medicine doctor by telephone during the study.

The exclusion criteria were: drug consumption with GI effect like prokinetics, acid-reducing drugs, bismuth, sedatives, laxatives, and drugs affecting the cholinergic system, macrolide an-

---

**Nardostachys jatamansi** DC for functional dyspepsia  
M. Mirzapour et al.
tibiotics, aspirin (> 325 mg/day), spasmodytics; any documented history of endoscopic esophagitis and peptic ulcer disease; concurrent major physical illness including cardiac or liver disease, inflammatory bowel disease, active thyroid disease, and vasculitis.

**Intervention**
The hydro-alcoholic (70%; ethanol/water) extract of the rhizomes of *N. jatamansi* in a form of fine brown powder was purchased from Soha-Jissa (plantation industries and medicinal plants processing Co. Mazandaran, Iran; Batch Number: 204086). The extract was chemically standardized as follows: valerenic acid: 0.26 %, total valepotriate: 8.69%, total phenolic content: 6.84% Gallic acid equivalent. The microbial limit tests were performed in accordance with the British pharmacopeia for herbal preparations [27]. Microbial count of the extract was below the standard limit based on the BP criteria for herbal preparations. Patients were asked to take 500mg *N. Jatamansi* capsules, 3 times daily before meals (1500 mg daily) for 30 days.

**Assessments**
The initial severity of the symptoms was assessed by the Gastrointestinal Symptom Rating Scale (GSRS). It was the only valid and reliable Persian version of existing questioner about the GI problem [28]. It contains 15 questions about the symptoms including: pain or discomfort in upper abdomen, heartburn, acid reflux, hunger pains, nausea, rumbling, bloating, burping(-belching), passing gas or flatus, constipation, diarrhea, loose stools, hard stools, urgent need to have a bowel movement, sensation of not completely emptying the bowels. For two main symptoms, early satiation and postprandial fullness we used a self-report of improvement at least 50% of symptoms. All patients were visited before the intervention and at week 4 (at the end of the treatment).

**Statistical analysis**
Data are shown as mean and standard deviation (SD) for the continuous variable and n (%) for the categorical variable. P-value was calculated using Wilcoxon Signed Ranks Test and Mann Whitney u test as appropriate. Statistical analyses were done using SPSS version 20.0. P<0.05 was considered as statistically significant.

**Results**
Of all 16 participants 56.2% (n = 9) were female, with the mean (SD) age of 47.3(9.4) years. The mean (SD) age of male was 49.6 (10.0) years. After intervention 2 male patients with heartburn were discontinued medication due to exacerbation of symptoms on the first day of treatment. General information for each of the remaining 14 patients has been reported in table 1.

**Table 1: Demographic and general information for each patient**

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Age, years</th>
<th>Sex</th>
<th>History of comorbidities</th>
<th>History of pervious treatment</th>
<th>Chief complaint</th>
<th>Initial GSRS total score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
<td>female</td>
<td>Hyper TG, cholesterol,</td>
<td>Omeprazole, domperidone</td>
<td>Sever bloating</td>
<td>52</td>
</tr>
<tr>
<td>2</td>
<td>55</td>
<td>male</td>
<td>No</td>
<td>Mebeverine, rulax® (Cassia angustifolia)</td>
<td>Sever bloating and constipation</td>
<td>65</td>
</tr>
<tr>
<td>3</td>
<td>54</td>
<td>male</td>
<td>DM</td>
<td>ALMG, omeprazole</td>
<td>Belching and postprandial fullness</td>
<td>34</td>
</tr>
<tr>
<td>4</td>
<td>48</td>
<td>female</td>
<td>History of breast cancer surgery</td>
<td>Pantoprazole</td>
<td>Belching, bloating</td>
<td>38</td>
</tr>
</tbody>
</table>
The mean (SD) GSRS score of the patients at baseline and follow-up (after 1 months) measurement was 41.30 (11.2) and 28.8 (10.3) respectively (with a difference of 12.5 (6.6); P-value = 0.001). This indicates that the GSRS score level decreased significantly after intervention among study population (30% decreases). Overall GSRS score at baseline and follow-up for each patient separately were shown in the figure 1.

<table>
<thead>
<tr>
<th></th>
<th>Age</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Symptoms</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>60</td>
<td>female</td>
<td>HTN, hyper TG</td>
<td>Domperidone</td>
<td>Bloating</td>
<td>36</td>
</tr>
<tr>
<td>6</td>
<td>32</td>
<td>female</td>
<td>No</td>
<td>Domperidone, pantoprazole</td>
<td>Bloating</td>
<td>54</td>
</tr>
<tr>
<td>7</td>
<td>39</td>
<td>male</td>
<td>No</td>
<td>Domperidone</td>
<td>Bleching and Post prandial fullness</td>
<td>41</td>
</tr>
<tr>
<td>8</td>
<td>39</td>
<td>male</td>
<td>No</td>
<td>Asacol, gabapentin</td>
<td>Epigastric pain and burning</td>
<td>43</td>
</tr>
<tr>
<td>9</td>
<td>39</td>
<td>female</td>
<td>MDD</td>
<td>Omeprazole, domperidone</td>
<td>Epigastric burning</td>
<td>37</td>
</tr>
<tr>
<td>10</td>
<td>52</td>
<td>female</td>
<td>Hypothyroidism, MDD</td>
<td>Domperidone</td>
<td>Bloating and belching and anorexia</td>
<td>50</td>
</tr>
<tr>
<td>11</td>
<td>41</td>
<td>female</td>
<td>Hyper cholestrolmia</td>
<td>anti-helicobacter pylori regimen</td>
<td>Bloating, belching, early satiety</td>
<td>35</td>
</tr>
<tr>
<td>12</td>
<td>51</td>
<td>female</td>
<td>Hyperthyroidism</td>
<td>Metronidazole, clarithromycin, dimethicone</td>
<td>Bloating and post prandial fullness</td>
<td>29</td>
</tr>
<tr>
<td>13</td>
<td>61</td>
<td>male</td>
<td>HTN, and 2 MIs</td>
<td>Domperidone, pantoprazole</td>
<td>Belching</td>
<td>21</td>
</tr>
<tr>
<td>14</td>
<td>43</td>
<td>female</td>
<td>No</td>
<td>Domperidone</td>
<td>Bloating, early satiety</td>
<td>43</td>
</tr>
</tbody>
</table>


Figure 1: Overall GSRS score separately measured for each patient at baseline (GSRS1) and follow-up (GSRS2)
The biggest difference between two measurements of GSRS was seen in the first patient who had severe bloating as chief complaint (Table 1). The comparison of the mean score of each question before and after intervention showed that the decrease of symptoms score in questions 1 (pain or discomfort in upper abdomen), 2 (heartburn), 6 (rumbling), 7 (bloating), 8 (belching), 9 (passing gas) and 15 (sensation of not completely emptying the bowels) were statistically significant (Table 2).

**Table 2:** Mean score of each question of the GSRS of all patients at baseline and follow-up measurement as well as their difference

<table>
<thead>
<tr>
<th>GSRS questions</th>
<th>Baseline measurement</th>
<th>Follow-up measurement (after 1 months)</th>
<th>Difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q 1 pain or discomfort in upper abdomen</td>
<td>3.71 (1.81)</td>
<td>2.36 (1.86)</td>
<td>-1.35 (1.15)</td>
<td>0.004</td>
</tr>
<tr>
<td>Q2 heartburn</td>
<td>2.6 (1.87)</td>
<td>1.71 (1.32)</td>
<td>-0.86 (1.35)</td>
<td>0.042</td>
</tr>
<tr>
<td>Q3 acid reflux</td>
<td>1.86 (1.10)</td>
<td>1.86 (1.10)</td>
<td>-0.00 (1.03)</td>
<td>0.89</td>
</tr>
<tr>
<td>Q4 hunger pains</td>
<td>2.43 (1.65)</td>
<td>1.79 (1.48)</td>
<td>-0.64 (1.39)</td>
<td>0.11</td>
</tr>
<tr>
<td>Q5 nausea</td>
<td>1.71 (1.27)</td>
<td>1.28 (0.47)</td>
<td>-0.43 (0.19)</td>
<td>0.16</td>
</tr>
<tr>
<td>Q6 rumbling</td>
<td>2.21 (1.05)</td>
<td>1.28 (0.61)</td>
<td>-0.93 (0.83)</td>
<td>0.006</td>
</tr>
<tr>
<td>Q7 bloating</td>
<td>4.93 (1.98)</td>
<td>2.71 (1.49)</td>
<td>-2.21 (1.31)</td>
<td>0.001</td>
</tr>
<tr>
<td>Q8 burping (belching)</td>
<td>3.50 (1.83)</td>
<td>2.00 (1.30)</td>
<td>-1.50 (1.22)</td>
<td>0.003</td>
</tr>
<tr>
<td>Q9 passing gas or flatus</td>
<td>5.21 (1.93)</td>
<td>2.71 (1.49)</td>
<td>-2.50 (1.34)</td>
<td>0.001</td>
</tr>
<tr>
<td>Q10 constipation</td>
<td>3.36 (2.27)</td>
<td>3.00 (1.88)</td>
<td>-0.36 (2.12)</td>
<td>0.26</td>
</tr>
<tr>
<td>Q11 diarrhea</td>
<td>1.21 (0.80)</td>
<td>1.07 (0.27)</td>
<td>-0.14 (0.53)</td>
<td>0.32</td>
</tr>
<tr>
<td>Q12 loose stools</td>
<td>1.21 (0.80)</td>
<td>1.07 (0.27)</td>
<td>-0.14 (0.53)</td>
<td>0.32</td>
</tr>
<tr>
<td>Q13 hard stools</td>
<td>3.07 (2.23)</td>
<td>2.78 (1.85)</td>
<td>-0.28 (1.14)</td>
<td>0.36</td>
</tr>
<tr>
<td>Q14 urgent need to have a bowel movement</td>
<td>1.28 (0.82)</td>
<td>1.07 (0.27)</td>
<td>-0.21 (0.58)</td>
<td>0.18</td>
</tr>
<tr>
<td>Q15 sensation of not completely emptying the bowels</td>
<td>3.0 (2.29)</td>
<td>2.07 (1.49)</td>
<td>-0.93 (1.49)</td>
<td>0.041</td>
</tr>
</tbody>
</table>

A: Data are shown as mean (SD)
B: P-value was calculated according to the Wilcoxon Signed Ranks Test

But symptoms like acid reflux, hunger pains, nausea, constipation, diarrhea, were not statistically significant. All of the patients who had chief complaint of early satiety and postprandial fullness (n = 5) reported complete relief of symptoms at the end of treatment period.

**Discussion and Conclusion**

In recent years some studies have demonstrated the increase of patients’ requests for holistic approach as well as alternative therapies for treatment of FD [29,30]. The effectiveness of phytotherapy, as one of main kinds of alternative treatments, on FD has not systematically been clarified. In this way, the assessment of the efficacy and safety of these herbal medications seems to be worthwhile. Persian medicine, has recommended numerous herbs for the treatment of dyspepsia symptoms which Indian valerian (N. jatamansi) is one of the most repetitive ones [31]. The main reported therapeutic effects of N. jatamansi in PM text books are in two main organs, stomach and brain [32]. Newly available reports of Indian valerian are mainly related to its effects on CNS [33,34]. Also, no clinical evidence of its effect
on gastrointestinal (GI) diseases have found in recent studies. Thus, this study would be considerable as first report of *N. jatamansi* effect on GI disorders in human.

There are some studies indicating phytotherapeutical approaches to dyspepsia mostly with the polyherbal formulations [35,36]. Many clinical studies have been performed on the STW5, a combination of nine plant extracts as a traditional Chinese herbal formula [37-39]. Comparing the results of different studies with results of this study, because of the difference in poly- and mono-herbal formulations and difference in outcome measurement tool, may not be correct. Bortolotti and his colleagues studied the efficacy of red pepper powder (2.5 g/day; before meals, for 5 weeks) in 30 patients with non-ulcer dyspepsia. They reported a decrease about 60% in the overall symptom score and the epigastric pain, fullness and nausea scores of the red pepper group at the end of the treatment. The present study demonstrated significant improvement of dyspeptic symptoms with decrease about 30% during the treatment with *N. jatamansi* hydroalcoholic extract in all 14 patients. However, the outcomes measurement tools of the two studies are not the same and the comparison may be incomplete. Other effective treatments were also reported with monoherbal formulations like artichoke leaf extract [40], *Glycyrrhiza glabra* [41], and with herb combinations like peppermint oil and caraway oil [14]. Whereas, most patients in the present study had refractory functional dyspepsia and experienced other therapeutic options, the results of this study could be the basis for further studies to reach the appropriate dosage form. We had two cases of patients with increased heartburn who had to stop taking medication. On the other hand, there was an increase in symptoms of epigastric pain and burning in some patients, but they were not willing to stop medication because of the satisfaction of the reduction of other symptoms like; rumbling, bloating, burping (belching), passing gas or flatus and sensation of not completely emptying the bowels. All patients with complaints of postprandial fullness and early satiety were reported more than 50% decrease in their symptoms. According to these results and some animal studies support the gastroprotective effect of the hydroalcoholic extract of *N. jatamansi* [26], we can hypothesize that this drug is more effective in people with postprandial distress symptoms versus epigastric pain syndrome.

In this case series we had 2 patients who had simultaneous functional dyspepsia and psychological disorder that had been under the appropriate treatment. After the treatment with *N. jatamansi* for their FD related problems, patients reported a decrease in psychological symptoms (such as improving sleep status and decreasing stress). We did not define the improvement of psychological symptoms with appropriate measurement tool since the beginning of the study, thus we cannot accurately comment on this section at this time. However, *N. jatamansi* has been shown to have antidepressant activity in preclinical studies [42]. In a mechanistic view, its extract has been indicated to cause an overall increase in the norepinephrine, dopamine, serotonin, 5-hydroxyindoleacetic acid (5-HIAA), and gamma-aminobutyric acid (GABA), in rats [43]. Evidence from recent researches has also demonstrated that *N. jatamansi* may increase levels of neurotransmitter acetylcholine in the synaptic space, and improve cholinergic functions via acetylcholinesterase inhibitory effect [44]. The neurotransmitters of autonomic nervous system and cholinergic system might influence gastric accommodation and emptying [45]. As gastric dysmotility has been indicated as supposed cause of FD, acetylcholinesterase inhibitors might effectively treat patients with FD [46]. Considering the simultaneous effect of *N. jatamansi* in the field of CNS and GI and respect to the importance of gut–brain axis and
the role of psychological disorders, especially the anxiety and depression, in pathophysiology of functional dyspepsia [47-50], we can hypothesize the effectiveness of *N. jatamansi* on patients with simultaneous digestive and neurological involvement.

Additionally, *N. jatamansi* has been shown to have pharmacological activities such as anti-hyperglycemic, anti-hypertensive and anti-inflammatory effects through the inhibitory activities on each respectively related key enzymes like α-amylase, angiotensin-converting enzyme and lipoxygenase [51,52]. Whereas, any side effect report has not reported by patients with other underlying conditions such as hypothyroidism, high blood pressure and diabetes, it has suggested that *N. jatamansi* be used for further studies in FD patients with these underlying diseases.

**Statement of Ethics**
The study protocol was approved by the Ethics Committee of Babol University of Medical Sciences, Babol, Iran.

**Funding Sources**
Babol University of Medical Sciences supports this study.

**Conflict of Interest**
None.

**Acknowledgments**
None.

**References**
Nardostachys jatamansi DC for functional dyspepsia

M. Mirzapour et al.


